Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 22 min ago
Peer-reviewedLicence not statedNew England Journal of Medicine

In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia

  • Scott B. Vafai1
  • Jörg Täubel2,3
  • Thomas Ashdown2
  • Riyaz S. Patel4,5
  • Sadaf Diamondali4
  • Jaimini Cegla6
  • Handrean Soran7
  • Bilal Bashir7
  • Alexander Abitbol8,9
  • Daniel Gaudet10,11
  • Alex Lauzière10,11
  • Liam R. Brunham12,13
19 more authors
  • David Ernest Newby14
  • Stephen J Nicholls15
  • Russell S. Scott16
  • Jane Kerr16
  • Jean‐Claude Tardif17
  • Catherine Lunken18
  • Steve Eric Humphries5
  • Verena Karsten1
  • Patrick D. Tyler1
  • Xinyan Zhang1
  • Nidal Huniti1
  • Patrick A. Flight1
  • Chelsey J. Jensen1
  • Rick Falzone1
  • Joseph C. Biedenkapp1
  • Troy Lister1
  • Leslie E. Stolz1
  • Amit V. Khera1
  • Sekar Kathiresan1
18 affiliations
  1. 1Verve Therapeutics, a wholly owned subsidiary of Eli Lilly, Boston
  2. 2Richmond Pharmacology, London
  3. 3St. George’s University of London, London
  4. 4Barts Health NHS Trust, London
  5. 5Institute of Cardiovascular Science, University College London, London
  6. 6Imperial College London, London
  7. 7National Institute for Health and Care Research–Wellcome Trust Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, United Kingdom
  8. 8Centricity Research, Toronto
  9. 9LMC Diabetes and Endocrinology, Toronto
  10. 10Department of Medicine, Université de Montréal, Montreal
  11. 11ECOGENE-21 Clinical Research Center, Chicoutimi, QC, Canada
  12. 12Department of Medicine, University of British Columbia, Vancouver, Canada
  13. 13Healthy Heart Program Prevention Clinic, St. Paul’s Hospital, Vancouver, BC, Canada
  14. 14British Heart Foundation Centre for Research Excellence, University of Edinburgh, Edinburgh
  15. 15Victorian Heart Institute, Monash University, Melbourne, VIC, Australia
  16. 16New Zealand Clinical Research, Christchurch, New Zealand
  17. 17Montreal Heart Institute, Université de Montréal, Montreal
  18. 18University College London Hospitals NHS Foundation Trust, London
Open at sourcePDFDOICite

Related

  1. Little Evidence of Atherosclerosis in a Middle-aged Japanese Woman with Familial Hypercholesterolemia Carrying PCSK9 (p.Glu32Lys) and ABCG8 (p.Ile419Asn) Variants despite Elevated Lipoprotein (a) Levels
    Kazuto Aono, Junji Kobayashi, Hayato Tada +2
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaJ-STAGE
  2. Integration of molecular docking, molecular dynamics simulations, and free energy calculations identifies a novel flavonoid glycoside as a PCSK9 inhibitor for hypercholesterolemia
    Yanwei Wang, Xian Cheng, Fang Lin +4
    Scientific ReportsPeer-reviewedCC BYFull textGeneral medicineDOAJ
  3. Integrative ALS therapy: gene targeted therapy by base editing and potential exercise rehabilitation as synergistic strategies for functional recovery
    Kwangjun Lee, Taejin Kwak, Wonil Park
    Physical activity and nutritionPeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  4. Pathway-wide base editing charts chemical-genetic interactions in MAPK signaling
    J. Woods, C. X. Y. Hu, D. M. Jang +6
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  5. A base-editing and auxotrophic selection platform for linking epigenetic regulators to silent biosynthetic gene clusters in Aspergillus nidulans.
    Meng Pang, Donghui Guo, Yanling Li +9
    Synthetic and systems biotechnologyPeer-reviewedCC BY-NC-NDFull textPharmacology & toxicologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{vafai2026vivo,
  title = {{In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia}},
  author = {Scott B. Vafai and Jörg Täubel and Thomas Ashdown and Riyaz S. Patel and Sadaf Diamondali and Jaimini Cegla and Handrean Soran and Bilal Bashir and Alexander Abitbol and Daniel Gaudet and Alex Lauzière and Liam R. Brunham and David Ernest Newby and Stephen J Nicholls and Russell S. Scott and Jane Kerr and Jean‐Claude Tardif and Catherine Lunken and Steve Eric Humphries and Verena Karsten and Patrick D. Tyler and Xinyan Zhang and Nidal Huniti and Patrick A. Flight and Chelsey J. Jensen and Rick Falzone and Joseph C. Biedenkapp and Troy Lister and Leslie E. Stolz and Amit V. Khera and Sekar Kathiresan},
  journal = {New England Journal of Medicine},
  year = {2026},
  month = may,
  doi = {10.1056/nejmoa2601283},
  url = {https://www.research.ed.ac.uk/en/publications/4b6400b6-f99c-4a8b-8633-0ff6db15e901},
}
RIS
TY  - JOUR
TI  - In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia
AU  - Scott B. Vafai
AU  - Jörg Täubel
AU  - Thomas Ashdown
AU  - Riyaz S. Patel
AU  - Sadaf Diamondali
AU  - Jaimini Cegla
AU  - Handrean Soran
AU  - Bilal Bashir
AU  - Alexander Abitbol
AU  - Daniel Gaudet
AU  - Alex Lauzière
AU  - Liam R. Brunham
AU  - David Ernest Newby
AU  - Stephen J Nicholls
AU  - Russell S. Scott
AU  - Jane Kerr
AU  - Jean‐Claude Tardif
AU  - Catherine Lunken
AU  - Steve Eric Humphries
AU  - Verena Karsten
AU  - Patrick D. Tyler
AU  - Xinyan Zhang
AU  - Nidal Huniti
AU  - Patrick A. Flight
AU  - Chelsey J. Jensen
AU  - Rick Falzone
AU  - Joseph C. Biedenkapp
AU  - Troy Lister
AU  - Leslie E. Stolz
AU  - Amit V. Khera
AU  - Sekar Kathiresan
PY  - 2026
DA  - 2026/05/25
JO  - New England Journal of Medicine
DO  - 10.1056/nejmoa2601283
UR  - https://www.research.ed.ac.uk/en/publications/4b6400b6-f99c-4a8b-8633-0ff6db15e901
SN  - 0028-4793
SN  - 0096-6762
SN  - 1533-4406
SN  - 2331-4710
ER  -